Samsung Medical Center Announces World’s First Results of Single-Port Robotic Surgery for Esophageal Cancer
No Significant Difference in Safety Compared to Multi-Port Surgery...
Reduced Intraoperative Bleeding Observed
Minimally Invasive Approaches May Expand in Complex Esophageal Cancer Operations
The safety of single-port robotic surgery, which utilizes only one incision, has been confirmed even for esophageal cancer operations.
Professor Sungyong Park, Thoracic and Esophageal Surgery, Samsung Medical Center. Samsung Medical Center
View original imageOn June 17, Samsung Medical Center announced that the research team led by Sungyong Park, Professor of Thoracic and Esophageal Surgery, had published the results of single-port robotic surgery for esophageal cancer in the international journal “Annals of the Japanese Esophageal Society.” This is the first time that the outcomes of single-port robotic surgery for esophageal cancer, performed via a thoracic approach between the ribs, have been reported in an official academic journal.
The research team compared and analyzed single-port and conventional multi-port robotic surgeries in patients with esophageal cancer who underwent robotic surgery at Samsung Medical Center between December 2024 and November 2025. The study included 104 cases of multi-port surgery and 21 cases of single-port surgery.
Single-port robotic surgery is a minimally invasive technique in which both the camera and surgical instruments are inserted through a single incision, unlike the conventional method that requires multiple incisions in the chest or abdomen. While it offers the advantage of reducing the burden on patients, its application in esophageal cancer has been limited due to the high level of difficulty associated with the long anatomical structure connecting the neck, chest, and abdomen.
In particular, upper mediastinal lymph node dissection, which is crucial for esophageal cancer, has been challenging to perform using the conventional single-port approach. To overcome this limitation, the research team applied a thoracic approach through the intercostal space.
The analysis showed no significant differences between single-port and multi-port surgeries in terms of key indicators such as operation time, number of dissected lymph nodes, length of hospital stay, postoperative pain, and complication rates. The R0 resection rate, which indicates complete tumor removal, was also similar between the two methods. However, the amount of intraoperative blood loss was lower in the single-port group.
Professor Park stated, “We have confirmed the safety and validity of single-port surgery for esophageal cancer,” and added, “We will continue to refine the surgical technique to further reduce patient pain and improve quality of life.”
The Department of Thoracic and Esophageal Surgery at Samsung Medical Center has accumulated extensive experience in esophageal cancer surgery in Korea. In 2023, the department introduced the first dedicated robotic surgery system for thoracic and esophageal surgery in Asia, and in 2025, it was designated as the nation’s first robotic surgery epicenter. Of the 245 esophageal cancer surgeries performed at Samsung Medical Center in 2025, 79% were conducted using robotic surgery. During the same period, both the 30-day postoperative mortality rate and in-hospital mortality rate were 0%.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Currently, the department is conducting research to establish a cohort for preparing clinical trials aimed at addressing the unmet needs and improving the quality of life of esophageal cancer survivors by the end of 2027. Hongkwan Kim, Head of the Department of Thoracic and Esophageal Surgery at Samsung Medical Center, commented, “We will continue our research to enable more accurate diagnosis and optimized treatment for esophageal cancer.”
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.